Case Report

Near-Miss Diagnoses of Solitary Bladder Tumors Highlight the Importance of Immunohistochemical Staining

Van Schloegel, Syed M. Alam, Katie Dennis, Jeffrey Holzbeierlein, and John A. Taylor III

Department of Urology, University of Kansas Health System, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA

Correspondence should be addressed to John A. Taylor III; jtaylor27@kumc.edu

Received 14 July 2020; Accepted 8 December 2020; Published 17 December 2020

Academic Editor: Apul Goel

Copyright © 2020 Van Schloegel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We report three cases of prostate adenocarcinoma appearing as bladder masses and misdiagnosed as muscle-invasive bladder cancer (MIBC). Patients were referred for consideration for radical cystectomy after initial pathological diagnosis suggested poorly differentiated bladder cancer. Pathological review of tissue samples and subsequent immunohistochemical (IHC) staining confirmed advanced prostatic adenocarcinoma. Systemic therapy for prostate cancer was then initiated. These cases highlight the importance of patient history, physical exam, and IHC staining in consideration of a bladder mass, as these patients may have been subject to undue morbidity and surgical intervention without accurate pathologic diagnosis.

1. Introduction

In 2020, prostate cancer and bladder cancer are expected to be diagnosed in 191,930 and 81,400 new patients, respectively [1]. Standard of care for a new bladder mass includes transurethral resection of bladder tumor (TURBT) for treatment, diagnosis, and initial staging. TURBT specimens appearing as poorly differentiated carcinomas, particularly from trigonal tumors, may be misdiagnosed as urothelial in origin without clinical suspicion and further evaluation. It is uncommon for invasive prostate cancer to present away from the trigone, and these tumors may be at even higher risk for misdiagnosis. This may lead to undue morbidity and mortality associated with systemic therapy and surgery for presumed bladder cancer. We describe three cases of near-miss diagnoses that emphasize the importance of appropriate IHC staining based on clinical suspicion and patient history.

2. Case Presentations

2.1. Case 1. An 83-year-old male presented with an enhancing posterior wall bladder mass identified on surveillance imaging for a known renal mass. A 1.5 cm enhancing posterior peripheral zone prostate nodule was also noted. Cystoscopy revealed a nodular tumor in the posterior bladder wall with diffuse erythematous papillary changes along the right lateral wall. TURBT was performed with initial pathology reported as poorly differentiated bladder cancer. Of note, this patient had a history of localized prostate cancer previously treated with radiotherapy at a separate institute eight years prior. Prostate-specific antigen (PSA) was 2.57 ng/mL just prior to TURBT, with a PSA nadir of 0.2 ng/mL approximately three years prior. As such, additional IHC staining for GATA3 and NKX3.1 was performed on the TURBT specimen. This revealed diffuse strong nuclear staining of NKX3.1 with GATA3 positivity only seen in benign surface epithelium supporting a diagnosis of prostatic adenocarcinoma (Figure 1). Appropriate therapy for prostate cancer was subsequently initiated.

2.2. Case 2. An 80-year-old male presented to his local urologist for worsening obstructive voiding symptoms. Flexible cystoscopy revealed a dense bladder neck contracture. The patient underwent transurethral incision of this contracture at which time abnormal papillary tissue was seen at the bladder neck. Transurethral resection of this tissue was reported as muscle-invasive urothelial carcinoma with squamous differentiation, prompting referral for radical cystectomy at
our institution. The patient was counseled on surgery for MIBC but on physical exam was found to have a nodular prostate. As such, the patient was scheduled for repeat TURBT. PSA was drawn and measured 179.91 ng/mL, prompting internal pathological review. Initial tissue samples revealed poorly differentiated tumor cells with muscular invasion. Staining for NKX3.1 and GATA3 showed strong nuclear positivity in the tumor cells while GATA3 was appropriately confined to benign lymphocyte nuclei, confirming a diagnosis of prostate adenocarcinoma (Figure 2). TURBT was deferred, and staging studies revealed multiple sclerotic osseous lesions consistent with metastatic disease. Appropriate treatment for metastatic prostate cancer was initiated.

2.3. Case 3. A 79-year-old male underwent TURBT at an outside institution for a sessile lesion located at the bladder neck. Initial pathological review suggested a diagnosis of muscle-invasive urothelial carcinoma. As such, he was referred to our institution for consideration for radical cystectomy. The patient was noted to have a history of prostate adenocarcinoma previously treated with external beam radiation therapy. Digital rectal exam was unremarkable, and he did not have evidence of biochemical recurrence up to that time. Given this history and the location of his tumor, IHC staining for prostate cancer markers was pursued and revealed poorly differentiated prostate cancer. After further counseling, he went on to receive androgen deprivation therapy.

3. Discussion

In any patient with a bladder mass, a biopsy is needed to determine the grade, stage, and tissue origin. In patients previously treated with radiation therapy for prostate cancer, the tissue can appear as poorly differentiated carcinoma making organ specific cancer diagnosis challenging. The location of the mass may correlate with tissue of origin, although this is not always the case, as in our patient with tumors distinctly away from the trigone/bladder neck. Here, we demonstrate the importance of appropriate IHC staining in bladder tumor samples to differentiate urothelial malignancy from invasive prostate adenocarcinoma.

A retrospective analysis by Liu et al. demonstrated that up to 3.1% of all prostate cancers may originally be misdiagnosed as bladder cancer, although the sample size in this study was small [2]. Misdiagnosed tumors in this report appeared on imaging as masses along the bladder neck and trigone. There is little data available on the locations outside of these regions of the bladder that may harbor prostate cancer. In a recent meta-analysis, Zhao et al. demonstrated that the hazard ratio for the development of bladder cancer after radiation for prostate cancer is approximately 1.6 [3]. In the setting of prior
radiotherapy for prostate cancer, a high clinical suspicion for urothelial origin of bladder tumors may be warranted, but progression of the primary prostate cancer cannot be excluded.

Appropriate staining for prostate adenocarcinoma in these scenarios should include a panel of prostatic and urothelial markers, including PSA, NKX3.1, and GATA3. In a study by Mohanty et al. looking at high-grade prostate cancer of the bladder neck, PSA showed a sensitivity of only 25%, while NKX3.1 had a sensitivity of 100%. In this same study, both PSA and NKX3.1 showed 100% specificity with no false positives in urothelial carcinomas [4]. GATA3 has been shown to have a sensitivity of 80% as a urothelial marker in high-grade urothelial carcinoma and did not stain positive in any of the 38 high-grade prostatic adenocarcinoma samples in a study by Chang et al. [5]. The decision to pursue additional staining in the appropriate clinical context is key to avoiding the undue harm associated with misdiagnosis.

4. Conclusion

These cases emphasize the importance of a thorough history and physical exam in patients presenting with a new bladder mass. They also highlight the value of appropriate IHC staining of bladder tumor samples to distinguish prostatic and urothelial origin of malignancies in select patients, regardless of tumor location.

Abbreviations

MIBC: Muscle-invasive bladder cancer
TURBT: Transurethral resection of bladder tumor
PSA: Prostate-specific antigen
IHC: Immunohistochemical.

Conflicts of Interest

The authors have no conflicts of interest to report.

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, "Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," CA: A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] R. Liu, X. Xie, Z. Zhang, and Y. Xu, "A retrospective study of prostate cancer cases mimicking urothelial cell carcinoma of the bladder," European Journal of Medical Research, vol. 18, no. 1, p. 36, 2013.
[3] S. Zhao, Q. Xie, R. Yang et al., "High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis," Cancer Management and Research, vol. Volume 11, pp. 587–598, 2019.
[4] S. K. Mohanty, S. C. Smith, E. Chang et al., "Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas," American Journal of Clinical Pathology, vol. 142, no. 2, pp. 173–183, 2014.
[5] A. Chang, A. Amin, E. Gabrielson et al., "Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung," The American Journal of Surgical Pathology, vol. 36, no. 10, pp. 1472–1476, 2012.